Pfizer (PFE) Short-term Investments (2009 - 2026)

Pfizer (PFE) has reported Short-term Investments for 18 consecutive years, with $10.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short-term Investments fell 7.65% year-over-year to $10.7 billion in Q2 2026; TTM through Jun 2026 was $10.7 billion, a 7.65% decrease from a year earlier, with the FY2025 full-year figure at $12.5 billion, down 35.92% from the prior year.
• Short-term Investments was $10.7 billion for Q2 2026 at Pfizer, down from $11.4 billion in the prior quarter.
• Over five years, Short-term Investments peaked at $42.2 billion in Q3 2023 and troughed at $6.0 billion in Q2 2024.
• A 5-year average of $16.6 billion and a median of $13.0 billion in 2025 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 97.56% in 2024, down 85.65% in 2024.
• Over 5 years, Short-term Investments stood at $22.3 billion in 2022, then plunged by 55.92% to $9.8 billion in 2023, then soared by 97.56% to $19.4 billion in 2024, then tumbled by 35.92% to $12.5 billion in 2025, then retreated by 13.9% to $10.7 billion in 2026.
• The last three Short-term Investments figures came in at $10.7 billion (Q2 2026), $11.4 billion (Q1 2026), and $12.5 billion (Q4 2025), per Business Quant data.